FDA approves Novartis' Apligraf for treatment of diabetic foot ulcers.
The approval expands the use of Apligraf, which received marketing clearance in 1998 for use in the treatment of venous leg ulcers of greater than 1-month duration that have not adequately responded to conventional therapy alone. The companies say Apligraf is a bi-layered living skin substitute and is the only product of its kind approved for marketing in the US.
In a prospective, randomized pivotal trial, the use of Apligraf with standard care healed 56% of diabetic ulcers within 12 weeks, compared to 39% for standard care alone, Novartis and Organogenesis report. The product also healed the ulcers faster. The median time to closure was 65 days among wounds treated with Apligraf, compared with 90 days for wounds using standard care alone. The patients included in the trial had their ulcers at least 2 weeks prior to entering the study and failed to make good healing progress during the 1 week screening phase.
Contact: Geoffrey Cook, Novartis - (973) 781-5486, or Carol Hausner, Organogenesis - (781) 575-0775
|Printer friendly Cite/link Email Feedback|
|Article Type:||Brief Article|
|Date:||Jun 30, 2000|
|Previous Article:||Kids getting umbilical cord blood instead of BMT from HLA-identical siblings have lower GVHD.|
|Next Article:||Pittsburgh researchers begin clinical trial with VitaGen bio-artificial liver assist device.|